WHAT IS CLAIMED IS:

1. A method for modulating the plasma circulation half-life of an active agent, said method comprising:

(a) providing a liposome having free active agent and precipitated active agent encapsulated therein; and

(b) varying the amount of said active agent that is precipitated in said liposome.

2. The method of claim **1**, wherein step (b) comprises varying said active agent to lipid ratio.

3. The method of claim **2**, wherein said active agent to lipid ratio is varied by the addition of an empty liposome.

4. The method of claim **1**, wherein step (b) comprises varying the size of said liposome.

5. The method of claim **1**, wherein step (b) comprises adding a component that enhances precipitation of said active agent.

6. The method of claim **5**, wherein said component is a mono-, di-, tri-, or polyvalent anion.

7. The method of claim **1**, wherein step (b) comprises varying both said active agent to lipid ratio and the size of the liposome.

8. The method of claim **1**, wherein said active agent is an antineoplastic drug.

9. The method of claim **8**, wherein said antineoplastic drug is a camptothecin.

10. The method of claim **9**, wherein said camptothecin is a member selected from the group consisting of irinotecan, topotecan, 9-amino camptothecin, 10,11-methylenedioxy camptothecin, 9-nitro camptothecin, TAS 103, 7-(4-methyl-piperazino-methylene)-10, 11-ethylenedioxy-20(S)-camptothecin and 7-(2-N-isopropylamino)ethyl)-20(S)-camptothecin.

11. The method of claim **10**, wherein said camptothecin is topotecan.

12. The method of claim **1**, wherein said active antineoplastic drug is a vinca alkaloid.

13. The method of claim **12**, wherein said vinca alkaloid is a member selected from the group consisting of vincristine, vinblastine, vinorelbine and vindesine.

14. The method of claim **1**, wherein the precipitated active agent encapsulated in said liposome is at least 50% of said total active agent.

15. The method of claim **14**, wherein the precipitated active agent encapsulated in said liposome is at least 60% of said total active agent.

16. The method of claim **15**, wherein the precipitated active agent encapsulated in said liposome is at least 70% of said total active agent.

17. The method of claim **1**, wherein said liposome comprises sphingomyelin and cholesterol.

18. The method of claim **17**, wherein said liposome comprises sphingomyelin and cholesterol in a 55:45 ratio.

19. The method of claim **1**, wherein the plasma circulation half-life of said active agent is modulated for optimum efficacy.

20. The method of claim **1**, wherein the ratio of said active agent to lipid is about 0.005-1:1 (w/w).

21. The method of claim **20**, wherein the ratio of said active agent to lipid is about 0.05-0.9:1 (w/w).

22. The method of claim **21**, wherein the ratio of said active agent to lipid is about 0.1-0.5:1 (w/w).

23. A method for modulating the plasma circulation half-life of an active agent, said method comprising:

(a) providing a liposome having free active agent and precipitated active agent encapsulated therein; and

(b) adding a liposome with no encapsulated active agent.

24. The method of claim **23**, wherein the ratio of liposomes containing active agent to liposomes with no encapsulated agent is from about 1:0.5 to 1:1000.

25. The method of claim **24**, wherein the ratio of liposomes containing active agent to liposomes with no encapsulated agent is from about 1:1 to 1:100.

26. The method of claim **25**, wherein the ratio of liposomes containing active agent to liposomes with no encapsulated agent is from about 1:2 to 1:10.

27. The method of claim **26**, wherein the ratio of liposomes containing active agent to liposomes with no encapsulated agent is from about 1:3 to 1:5.

28. The method of claim **23**, wherein said active agent is an antineoplastic drug.

29. The method of claim **28**, wherein said antineoplastic drug is a camptothecin.

30. The method of claim **29**, wherein said camptothecin is a member selected from the group consisting of irinotecan, topotecan, 9-amino camptothecin, 10,11-methylenedioxy camptothecin, 9-nitro camptothecin, TAS 103, 7-(4-methyl-piperazino-methylene)-10, 11-ethylenedioxy-20(S)-camptothecin and 7-(2-N-isopropylamino)ethyl)-20(S)-camptothecin.

31. The method of claim **30**, wherein said camptothecin is topotecan.

32. A liposomal formulation, said liposomal formulation comprising:

a) an antineoplastic drug; and

b) a liposome having free antineoplastic drug and precipitated antineoplastic drug, wherein the precipitated antineoplastic drug in said liposome is at least 50% of the total antineoplastic drug.

33. The liposomal formulation of claim **32**, wherein said antineoplastic drug is a camptothecin.

34. The liposomal formulation of claim **33**, wherein said camptothecin is a member selected from the group consisting of irinotecan, topotecan, 9-amino camptothecin, 10,11-methylenedioxy camptothecin, 9-nitro camptothecin, TAS 103, 7-(4-methyl-piperazino-methylene)-10, 11-ethylenedioxy-20(S)-camptothecin and 7-(2-N-isopropylamino)ethyl)-20(S)-camptothecin.

35. The liposomal formulation of claim **34**, wherein said camptothecin is topotecan.

36. The liposomal formulation of claim **33**, wherein said antineoplastic drug is a vinca alkaloid.

37. The liposomal formulation of claim **32**, wherein the free antineoplastic drug and the precipitated antineoplastic drug are different.

38. The liposomal formulation of claim **36**, wherein said vinca alkaloid is a member selected from the group consisting of vincristine, vinblastine, vinorelbine and vindesine.

39. The liposomal formulation of claim **32**, wherein the ratio of said antineoplastic drug to lipid is about 0.005-1:1 (w/w).

40. The liposomal formulation of claim **39**, wherein the ratio of said antineoplastic drug: said lipid is about 0.05-0.9:1 (w/w).

41. The liposomal formulation of claim **40**, wherein the ratio of said antineoplastic drug: said lipid is about 0.1-0.5:1 (w/w).

42. The liposomal formulation of claim **32**, wherein said liposome comprises sphingomyelin and cholesterol.

43. The liposomal formulation of claim **42**, wherein said liposome comprises sphingomyelin and cholesterol in a 55:45 ratio.

44. The liposomal formulation of claim **32**, further comprising a liposome with no encapsulated active agent.

45. The liposomal formulation of claim **44**, wherein the ratio of liposomes containing active agent to liposomes with no encapsulated agent is from about 1:0.5 to 1:1000.

46. The liposomal formulation of claim **45**, wherein the ratio of liposomes containing active agent to liposomes with no encapsulated agent is from about 1:1 to 1:100.

47. The liposomal formulation of claim **46**, wherein the ratio of liposomes containing active agent to liposomes with no encapsulated agent is from about 1:2 to 1:10.

48. The liposomal formulation of claim **47**, wherein the ratio of liposomes containing active agent to liposomes with no encapsulated agent is from about 1:3 to 1:5.

49. A liposomal formulation, said liposomal formulation comprising:

a) an active agent;

b) a liposome having free active agent and precipitated active agent encapsulated therein; and

c) an empty liposome.

50. The liposomal formulation of claim **49**, wherein the ratio of liposomes containing said active agent to said empty liposomes is from about 1:0.5 to 1:1000.

51. The liposomal formulation of claim **50**, wherein the ratio of liposomes containing said active agent to said empty liposomes is from about 1:1 to 1:100.

52. The liposomal formulation of claim **51**, wherein the ratio of liposomes containing said active agent to said empty liposomes is from about 1:2 to 1:10.

53. The liposomal formulation of claim **52**, wherein the ratio of liposomes containing said active agent to said empty liposomes is from about 1:3 to 1:5.

54. The liposomal formulation of claim **49**, wherein said active agent is an antineoplastic drug.

55. The liposomal formulation of claim **54**, wherein said antineoplastic drug is a camptothecin.

56. The liposomal formulation of claim **55**, wherein said camptothecin is a member selected from the group consisting of irinotecan, topotecan, 9-amino camptothecin, 10,11-methylenedioxy camptothecin, 9-nitro camptothecin, TAS 103, 7-(4-methyl-piperazino-methylene)-10, 11-ethylenedioxy-20(S)-camptothecin and 7-(2-N-isopropylamino)ethyl)-20(S)-camptothecin.

57. The liposomal formulation of claim **56**, wherein said camptothecin is topotecan.

58. The liposomal formulation of claim **57**, wherein said antineoplastic drug is a vinca alkaloid.

59. The liposomal formulation of claim **58**, wherein said vinca alkaloid is a member selected from the group consisting of vincristine, vinblastine, vinorelbine and vindesine.

60. The liposomal formulation of claim **49**, wherein the ratio of said active agent to lipid is about 0.005-1:1 (w/w).

61. The liposomal formulation of claim **60**, wherein the ratio of said active agent to lipid is about 0.05-0.9:1 (w/w).

62. The liposomal formulation of claim **61**, wherein the ratio of said active agent to lipid is about 0.1-0.5:1 (w/w).

63. The liposomal formulation of claim **49**, wherein said liposome comprises sphingomyelin and cholesterol.